Merck's jobs axe is put to work

There's a lot of rumbling in the blogosphere about the Merck job-chopping block. Last fall Merck announced it would shed 6,800 jobs--and now, the drugmaker is lowering the boom. Or so we're told.

Derek Lowe at In the Pipeline is hearing firsthand from Merck folks that an across-the-board cutback in R&D is going on as we speak. Research types at all R&D sites are getting pink slips.

And with Merck and Schering-Plough destined to merge later this year, the job cuts are due to step up a notch. If the current round is part of the previously announced restructuring plan, they're just a warm-up for an expected 16,000 or so additional cuts. All told, Merck and Schering-Plough's workforce is expected to shrink by 15 percent.

- read the post at In The Pipeline

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.